Revotek

ApplicationChengdu, ChinaFounded 2014· One of 462 Application companies tracked by AMPulse

A pioneering regenerative medicine company specializing in biological additive manufacturing, specifically the world's first 3D bioprinted stem cell vascular grafts (REVOVAS) and proprietary 'Biosynsphere' bio-ink technology.

CEO / Founder: Professor Y. James Kang
Team Size: 51-200
Stage: Defunct
Total Funding: $41.4M
Latest Round: Corporate Round
Key Investors: Sichuan Languang Development (600466.SH), Chinese State 863 Program (Grants)

Technology & Products

Key Products

REVOVAS®: 3D bioprinted stem cell vascular transplant system, Biosynsphere® (Biological Bricks): Proprietary stem cell-based bio-ink, 3D Bio-vascular Printer: World's first specialized vascular bioprinting hardware, Medical Imaging Cloud Platform: AI-driven modeling system for personalized organ/tissue design, Bio-active Post-printing Treatment System

Technological Advantage

Combines stem cell biology with additive manufacturing and AI cloud modeling to achieve 'organ regeneration' rather than mere mechanical substitution; features a 1700+ day successful follow-up in non-human primate trials, the longest in the industry.

Differentiation

Value Proposition

Enables the creation of bio-active, personalized vascular grafts that integrate seamlessly with host tissue (endothelialization), eliminating the need for long-term anticoagulant medication and overcoming the limitations of synthetic or cadaveric grafts.

How They Differentiate

Revotek utilizes a proprietary 'spatial rotating bioprinting platform' and 'Biosynsphere' (stem cell biological bricks) to create living, scaffold-free vascular grafts that integrate and endothelialise within the host, unlike the needle-array (Kenzan) methods or synthetic scaffold approaches used by competitors.

Market & Competition

Target Customers

Patients with end-stage vascular diseases (e.g., Peripheral Arterial Disease - PAD), cardiovascular surgeons, and healthcare institutions requiring regenerative tissue solutions.

Industry Verticals

Regenerative Medicine, Cardiovascular Healthcare, Organ Manufacturing, Pharmaceutical Drug Screening, Biotechnology Research

Competitors

Regenovo Biotechnology (Hangzhou); Cyfuse Biomedical (Japan); Organovo (USA)

Growth & Milestones

Growth Metrics

NHC-backed FIH clinical path started 2022 with West China Hospital, but parent *ST蓝光 cut funding; board approved Revotek business shutdown (关停) Mar 2023 and asset disposal; R&D reported stagnant through 2024 filings. Legal entity still 存续 (subsidiary ~98.9%).

Major Milestones

2015: Launched the world’s first 3D biological vascular printer, 2016: Achieved world's first successful implantation of 3D bioprinted vessels in rhesus monkeys, 2019: Documented survival of implanted vessels reaching over 1000 days in animal models, 2022: Received National Health Commission approval for First-in-Human (FIH) clinical trials, 2024: Featured on CCTV-4 for leadership in clinical regenerative medicine

Notable Customers

West China Hospital of Sichuan University (Strategic Clinical Partner)

https://www.revotek.com.cn

Why this company matters

AMPulse analysis, not a company disclosure

Revotek occupies a distinctive position at the intersection of additive manufacturing and regenerative medicine, focusing on scaffold-free bioprinting of living vascular grafts. Unlike synthetic or cadaveric alternatives that require long-term anticoagulant medication, Revotek's approach aims to produce bio-active vessels that endothelialize and integrate fully with the host tissue, potentially eliminating the need for lifelong drug therapy.

The company's core technology centers on its proprietary 'Biosynsphere' bio-ink, which encapsulates stem cells in a nutrient shell. These units are deposited using a spatial rotating bioprinting platform to form functional, living vessels without an external scaffold. The REVOVAS system comprises the bioprinter, the bio-ink, and a post-printing treatment system, supported by an AI-driven medical imaging cloud platform for personalized tissue design.

Revotek's primary target is patients with end-stage vascular diseases such as peripheral arterial disease, with cardiovascular surgeons and healthcare institutions as key customers. The company has a strategic clinical partnership with West China Hospital of Sichuan University and received National Health Commission approval for first-in-human clinical trials in 2022. Preclinical data includes a 1700-plus-day successful follow-up in non-human primate trials, which the company claims is the longest in the industry.

The company competes with Regenovo Biotechnology, Cyfuse Biomedical, and Organovo, differentiating through its scaffold-free, stem-cell-based method versus needle-array or synthetic scaffold approaches. Key risks include the long and uncertain regulatory pathway for bioprinted living implants and the scalability of manufacturing personalized vascular grafts. Revotek has raised approximately $41.4 million from investors including Sichuan Languang Development and Chinese state grants.